Hyperprogressive Disease: Main Features and Key Controversies.
cancer
checkpoint inhibitors
hyperprogressive disease
immunotherapy
solid tumors
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
03 Apr 2021
03 Apr 2021
Historique:
received:
22
03
2021
revised:
31
03
2021
accepted:
31
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
14
5
2021
Statut:
epublish
Résumé
Along with the positioning of immunotherapy as a preferential treatment for a wide variety of neoplasms, a new pattern of response consisting in a sudden acceleration of tumor growth has been described. This phenomenon has received the name of "hyperprogressive disease", and several definitions have been proposed for its identification, most of them relying on radiological criteria. However, due to the fact that the cellular and molecular mechanisms have not been elucidated yet, there is still some debate regarding whether this fast progression is induced by immunotherapy or only reflects the natural course of some highly aggressive neoplasms. Moreover, contradictory results of trials including patients with different cancer types suggest that both the incidence, the associated factors and the implications regarding prognosis might differ depending on tumor histology. This article intends to review the main publications regarding this matter and critically approach the most controversial aspects.
Identifiants
pubmed: 33916696
pii: ijms22073736
doi: 10.3390/ijms22073736
pmc: PMC8038385
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Asociación Española Contra el Cáncer (AECC)
ID : PROYE16001ESCO
Organisme : Asociación Española Contra el Cáncer (AECC)
ID : CLJUN19010ARAS
Organisme : Departamento de Salud de Navarra
ID : BMED 050-2019
Organisme : Instituto de Salud Carlos III
ID : ISCIII-FEDER, FIS. PI17/02119
Références
Med Sci Monit. 2020 Oct 20;26:e924671
pubmed: 33077705
Clin Cancer Res. 2014 Jan 1;20(1):246-52
pubmed: 24240109
Nat Cancer. 2020 Dec;1(12):1153-1166
pubmed: 33644766
Cancer Immunol Res. 2017 May;5(5):417-424
pubmed: 28411193
Immunity. 2013 Feb 21;38(2):275-84
pubmed: 23333074
Immunity. 2016 Nov 15;45(5):1135-1147
pubmed: 27851914
Clin Cancer Res. 2017 Sep 1;23(17):5074-5081
pubmed: 28320758
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
Cancer. 2019 Apr 15;125(8):1341-1349
pubmed: 30768786
Ann Oncol. 2019 Jun 1;30(6):998-1004
pubmed: 30895304
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33188037
J Immunol. 2009 Dec 15;183(12):7631-4
pubmed: 19923467
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17945-50
pubmed: 24127572
JAMA Oncol. 2018 Mar 1;4(3):351-357
pubmed: 29327044
Clin Cancer Res. 2019 Feb 1;25(3):989-999
pubmed: 30206165
Neuro Oncol. 2019 Feb 19;21(3):404-414
pubmed: 30107606
Sci Transl Med. 2012 May 16;4(134):134ra62
pubmed: 22593175
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33051342
ESMO Open. 2019 May 21;4(3):e000488
pubmed: 31231567
JAMA Oncol. 2020 Jul 1;6(7):1039-1046
pubmed: 32525513
Cancer Cell. 2013 Feb 11;23(2):249-62
pubmed: 23410977
Clin Cancer Res. 2020 Apr 15;26(8):1846-1855
pubmed: 31757877
Ann Oncol. 2019 Aug 1;30(8):1381-1392
pubmed: 31114846
Front Oncol. 2020 Sep 04;10:1706
pubmed: 33014846
Sci Rep. 2020 Feb 27;10(1):3565
pubmed: 32107407
Lancet Oncol. 2018 Sep;19(9):1180-1191
pubmed: 30120041
Oncoimmunology. 2013 Dec 1;2(12):e26968
pubmed: 24498562
Gastric Cancer. 2019 Jul;22(4):793-802
pubmed: 30627987
Ann Oncol. 2019 Jul 1;30(7):1104-1113
pubmed: 30977778
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250
pubmed: 28351930
BMC Cancer. 2019 Jul 17;19(1):705
pubmed: 31315610
Ann Oncol. 2017 Jul 1;28(7):1605-1611
pubmed: 28419181
Cancers (Basel). 2019 Nov 01;11(11):
pubmed: 31683809
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008
pubmed: 31028147
Cancer Treat Rev. 2020 Dec;91:102116
pubmed: 33157360
Oncoimmunology. 2018 Jan 29;7(4):e1408747
pubmed: 29632720
Case Rep Oncol Med. 2016;2016:1075641
pubmed: 28116195
JAMA Oncol. 2018 Nov 1;4(11):1543-1552
pubmed: 30193240
Cancer Immunol Res. 2020 Jan;8(1):108-119
pubmed: 31719058
Cancers (Basel). 2020 Feb 04;12(2):
pubmed: 32033028